Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor

Clinical Microbiology and Infection

Volumn 22, Issue 11, 2016, Pages 946.e1-946.e8

  Cerva, C ^a   Colagrossi, L ^a   Maffongelli, G ^a   Salpini, R ^a   Di Carlo, D ^a   Malagnino, V ^a   Battisti, A ^a   Ricciardi, A ^a   Pollicita, M ^a   Bianchi, A ^a   Picardi, A ^a   Cudillo, L ^a   Cerretti, R ^a   De Angelis, G ^a   Cantonetti, M ^a   Andreoni, M ^a   Perno, C F ^a   Arcese, W ^a   Svicher, V ^a   Sarmati, L ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Haematological stem cell transplantation; HBV infection; HBV reactivation; Lamivudine; Prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; STEROID; TENOFOVIR; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE D; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEROLOGY; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REACTIVATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; HETEROZYGOTE; IMMUNOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VIRUS ACTIVATION;

ADULT; CARRIER STATE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84995390477     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.07.021     Document Type: Article

References (51)

1. [1] Oketani, M., Ido, A., Nakayama, N., Takikawa, Y., Naiki, T., Yamagishi, Y., et al., Intractable Hepato-Biliary Diseases Study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43:2 (2013), 97–105.
2. [2] Liang, R., Lau, G.K.K., Kwong, Y.L., Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers. J Clin Oncol 17 (1999), 394–398.
3. [3] Lau, G.K.K., Hepatitis B reactivation after chemotherapy: two decade of clinical research. Hepatol Int 2 (2008), 152–162.
4. [4] Koo, Y.X., Tay, M., Teh, Y.E., Teng, D., Tan, D.S., Tan, I.B., et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 90:10 (2011), 1219–1223.
5. [5] Seto, W.K., Chan, T.S., Hwang, Y.Y., Wong, D.K., Fung, J., Liu, K.S., et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32:33 (2014), 3736–3743.
6. [6] Dong, H.J., Ni, L.N., Sheng, G.F., Song, H.L., Xu, J.Z., Ling, Y., Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol 57:3 (2013), 209–214.
7. [7] Loomba, R., Rowley, A., Wesley, R., Liang, T.J., Hoofnagle, J.H., Pucino, F., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148 (2008), 519–528.
8. [8] European Association For The Study Of The Liver, EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
9. [9] Weinbaum, C.M., Williams, I., Mast, E.E., Wang, S.A., Finelli, L., Wasley, A., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:RR-8 (2008), 1–20.
10. [10] Lee, R.S., Bell, C.M., Singh, J.M., Hicks, L.K., Hepatitis B screening before chemotherapy: a survey of practitioners’ knowledge, beliefs, and screening practices. J Oncol Pract 8:6 (2012), 325–328.
11. [11] Hwang, J.P., Fisch, M.J., Lok, A.S., Zhang, H., Vierling, J.M., Suarez-Almazor, M.E., Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer, 13, 2013, 534.
12. [12] Zurawska, U., Hicks, L.K., Woo, G., Bell, C.M., Krahn, M., Chan, K.K., et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30:26 (2012), 3167–3173.
13. [13] Kusumoto, S., Tobinai, K., Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematology Am Soc Hematol Educ Program 2014:1 (2014), 576–583.
14. [14] Lalazar, G., Rund, D., Shouval, D., Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:5 (2007), 699–712.
15. [15] Milazzo, L., Corbellino, M., Foschi, A., Micheli, V., Dodero, A., Mazzocchi, A., et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis 14:1 (2012), 95–98.
16. [16] Hwang, J.P., Barbo, A.G., Perrillo, R.P., Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat, 2014 Sep 15, 10.1111/jvh.12305 [Epub ahead of print].
17. [17] Nakamoto, S., Kanda, T., Nakaseko, C., Sakaida, E., Ohwada, C., Takeuchi, M., et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for Prevention and treatment. Int J Mol Sci 15:11 (2014), 21455–21467.
18. [18] Viganò, M., Vener, C., Lampertico, P., Annaloro, C., Pichoud, C., Zoulim, F., et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 46:1 (2011), 125–131.
19. [19] Gupta, A., Punatar, S., Gawande, J., Bagal, B., Mathew, L., Bhat, V., et al. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. Hematol Oncol, 2015 Feb 18, 10.1002/hon.2195.
20. [20] Liang, R., How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:14 (2009), 3147–3153.
21. [21] Mikulska, M., Nicolini, L., Signori, A., Rivoli, G., Del Bono, V., Raiola, A.M., et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 20:10 (2014), O694–O701.
22. [22] Reddy, N.M., Savani, B.N., Hepatitis B reactivation in patients with hematological malignancies and stem cell transplantation. J Blood Lymph, 4, 2013, 114.
23. [23] Tohme, R.A., Bulkow, L., Homan, C.E., Negus, S., McMahon, B.J., Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001–2010. J Clin Virol 58:2 (2013), 396–400.
24. [24] Seth, P., Alrajhi, A.A., Kagevi, I., Chaudhary, M.A., Colcol, E., Sahovic, E., et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30:3 (2002), 189–194.
25. [25] Sarri, G., Westby, M., Bermingham, S., Hill-Cawthorne, G., Thomas, H., Guideline Development Group. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ, 346, 2013, f3893.
26. [26] Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., et al., Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:5 (2007), 397–408.
27. [27] Raimondo, G., Allain, J.P., Brunetto, M.R., Buendia, M.A., Chen, D.S., Colombo, M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008), 652–657.
28. [28] Rossi, D., Sala, L., Minisini, R., Fabris, C., Falleti, E., Cerri, M., et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 50:4 (2009), 604–611.
29. [29] Zeldis, J.B., Mugishima, H., Steinberg, H.N., Nir, E., Gal, R.P., In vitro Hepatitis B Virus infection of human bone marrow cells. J Clin Invest 78 (1986), 411–417.
30. [30] Shi, Y., Lan, Y., Cao, F., Teng, Y., Li, L., Wang, F., et al. Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients. J Viral Hepat 21:7 (2014), e39–e47.
31. [31] Mallet, V., van Bömmel, F., Doerig, C., Pischke, S., Hermine, O., Locasciulli, A., et al., ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). The Lancet Infectious Diseases 16:5 (2016), 606–617.
32. [32] Di Bartolomeo, P., Santarone, S., De Angelis, G., Picardi, A., Cudillo, L., Cerretti, R., et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 121:5 (2013), 849–857.
33. [33] Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:4 (1974), 295–304.
34. [34] Salpini, R., Colagrossi, L., Bellocchi, M.C., Surdo, M., Becker, C., Alteri, C., et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 61:3 (2015), 823–833.
35. [35] Colson, P., Borentain, P., Coso, D., Motte, A., Aurran-Schleinitz, T., Charbonnier, A., et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology 484 (2015), 354–363.
36. [36] Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect 65:2 (2012), 180–183.
37. [37] Martel, N., Cotte, L., Trabaud, M.A., Trepo, C., Zoulim, F., Gomes, S.A., et al. Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape. J Infect Dis 205:11 (2012), 1757–1761.
38. [38] Borentain, P., Colson, P., Coso, D., Bories, E., Charbonnier, A., Stoppa, A.M., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 17 (2010), 807–815.
39. [39] Hammond, S.P., Borchelt, A.M., Ukomadu, C., Ho, V.T., Baden, L.R., Marty, F.M., Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15 (2009), 1049–1059.
40. [40] Kempinska, A., Kwak, E.J., Angel, J.B., Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 41 (2005), 1277–1282.
41. [41] Knöll, A., Boehm, S., Hahn, J., Holler, E., Jilg, W., Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 14 (2007), 478–483.
42. [42] Giaccone, L., Festuccia, M., Marengo, A., Resta, I., Sorasio, R., Pittaluga, F., et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 16:6 (2010), 809–817.
43. [43] European Association for the Study of the Liver, EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
44. [44] Muñoz, S.J., Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl, 8(10 Suppl. 1), 2002 S82–7. Review.
45. [45] Frange, P., Leruez-Ville, M., Neven, B., Mascard, L., Moshous, D., Touzot, F., et al. Safety of hematopoietic stem cell transplantation from hepatitis B core antibodies-positive donors with low/undetectable viremia in HBV-naïve children. Eur J Clin Microbiol Infect Dis 33:4 (2014), 545–550.
46. [46] Hui, C.K., Sun, J., Au, W.Y., Lie, A.K., Yueng, Y.H., Zhang, H.Y., et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42:6 (2005), 813–819.
47. [47] Gonzalez, M., Règine, V., Piccinini, V., Vulcano, F., Giampaolo, A., Hassan, H.J., Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 45:10 (2005), 1670–1675.
48. [48] Raimondo, G., Caccamo, G., Filomia, R., Pollicino, T., Occult HBV infection. Semin Immunopathol 35:1 (2013), 39–52.
49. [49] Coppola, N., Loquercio, G., Tonziello, G., Azzaro, R., Pisaturo, M., Di Costanzo, G., et al. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol 58:1 (2013), 315–317.
50. [50] Bock, C.T., Tillmann, H.L., Torresi, J., Klempnauer, J., Locarnini, S., Manns, M.P., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:2 (2002), 264–273.
51. [51] Matthews, G.V., Bartholomeusz, A., Locarnini, S., Ayres, A., Sasaduesz, J., Seaberg, E., et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20:6 (2006), 863–870.